

8. Rabier, M. Farber, E. Wilkinson, D.: Neuropeptides Modulate Leukotriene B4 Mitogenicity Toward Cultured Human Keratinocytes. *J Invest Dermatol* 1993; 100: 132-6.
9. Paus, R. Heinzelman, T. Schultz, K. Fukert, J. Fechner, K. Czrnetzki, B.: Hair Growth Induction by Substance P. *Eur J. Pharmacol* 1993; 249: 281-6.
10. Donnerer, J. Shuligoi, R. Stein, C. Increased content and transport of substance P and Calcitonin Gene-related peptide in sensory nerves innervating inflamed tissue: Evidence for a regulatory function of nerve growth factor in vivo. *Neuroscience* 1992; 49(3):693-8.
11. Buckley, T.L. Brain, S.D. Collins, P.D. Williams, T.J.: Inflammatory edema induced by interactions between IL-1 and the neuropeptide Calcitonin Gene-related peptide. *J Immunol* 1991; 146(10): 3424-3430.
12. Kishimoto, S.: The regeneration of Substance P-Containing nerve Fibers in the Process of Burn Wound Healing in the Guinea Pig. *J Invest dermatol* 1984; 83: 219-23.
13. Slominski, A. Paus, R. Wortsman, J.: On the potential role of proopiomelanortin in skin physiology and pathology. *Mol Cell Endocrinol* 1993; 93: C1-C6.
14. Blalock, I.E.: The syntax of immune-neuroendocrine communication. *Immunol Today* 1994; 15(11): 504-10.
15. Khansari, D. Murgo, A. Faith, R.: Effects of Stress on the immune system. *Immunol Today* 1990; 11(5):170-5
16. Ottaway, C. Husband, A.: The influence of neuroendocrine pathway on lymphocyte migration. *Immunol Today* 1994; 15(11): 511-17.
17. Farber, E. Lanigan, S. Rein, G.: The role of Psychoneuroimmunology in the pathogenesis of psoriasis. *Cutis* 1990; 16:314-322.
18. Glinski, W. Brodecka, H. Glinska-Ferenz, M. Kowalski, D.: Neuropeptides in Psoriasis: Possible role of Beta-endorphin in the pathomechanism of the disease. *Int J Dermatol* 1994; 33(5): 356-60.
19. Farber, E. Rein, G. Lanigan, S.: Stress and Psoriasis. *Int J. Dermatol* 1991; 30(1): 8-12.
20. Eady, D.J.: Neuropeptides in Psoriasis: An immunocytochemical and radioimmunoassay study. *J Invest Dermatol* 1991; 96:434-8.
21. Pincelli, C. Fantini, F. Romualdi, P. Sevigani, C. Lesa, G. Benassi, L. et al.: Substance P is Diminished and Vasoactive Intestinal Peptide is augmented in Psoriatic lesions and these Peptides exert disparate effects on the Proliferation of Cultured Human Keratinocytes. *J Invest Dermatol* 1992; 98:241-7.
22. Karanth, S. Springall, D. Lucas, S. Levy, D. Ashby, P. Levene, M. Polak, J.: Changes in nerves and Neuropeptides in skin from 100 leprosy patients investigated by Immunocytochemistry. *J Pathol* 1989; 157: 15-26.
23. Lotti, T. Tsampau, D. Teofoli, P. Bend, M. Ghersetich I. Dahm, M. et al.: Neuropeptidergic acral dysesthesia: A new entity. *Int J Dermatol* 1993; 32(3): 198-9.
24. Cooper, K.: Atopic Dermatitis: Recent Trends in Pathogenesis and Therapy. *J Invest Dermatol* 1994; 102: 128-37.
25. Fantini, F. Baraldi, A. Sevigani, C. Spattini, A. Pincelli, C. Giannetti, A.: Cutaneous Innervation in Chronic Renal Failure Patients. *Act Derm Venereol (Stockh)* 1992; 72: 102-5.
26. Crowe, R. Parkhouse, N. McGrouther, D. Burnstock, G.: Neuropeptide-containing nerves in painful hypertrophic human scar tissue. *Br J Dermatol* 1994; 130: 444-52.
27. Anand, P. Springall, D. Blank M. Sellu, D. Polak, J. Bloom, S.: Neuropeptides in skin disease: Increased VIP in eczema and psoriasis but not axillary hyperhidrosis. *Br J Dermatol* 1991; 124: 547-9.
28. Abadia-Molina, F. Tercedor, I.: Implicaciones patogénicas de los neuropéptidos en el prurigo nodular. *Piel*. 1993; 8:218-9.
29. Abadia-Molina, F. Burrows, N. Russell-Jones, R. Terenghi, G. Polak, J.: Increased sensory neuropeptides in nodular prurigo: a quantitative immunohistochemical analysis. *Br J Dermatol* 1992; 127: 344-51.
30. Gutwald, J. Goebeler, M. Sorg, C.: Neuropeptides enhance Irritant and Allergic Contact Dermatitis. *J Invest Dermatol* 1991; 96: 695-8.
31. Abadie, M. Senior, H. Bleehen, S. Gawkrödger, D.: Neuropeptides and neuronal marker studies in vitiligo. *Br J Dermatol* 1994; 131:16-5.
32. Bunker, C. Foreman, J. Dowd, P.: Digital Cutaneous Vascular Response to Histamine and Neuropeptides in Raynaud's Phenomenon. *J Invest Dermatol* 1991; 96:314-7.

Shigeruko, L., Takako, T., Fujin, O. *Arch Dermatol*, 1995, 131:399-401.

## “Treatment of Chromomycosis with Oral High-Dose Amphotericin B”

Paciente masculino de 54 años de edad, que notó una erupción en la porción superior de abdomen de crecimiento lento teniendo una configuración creciente, arciforme que aumenta de tamaño formando un patrón anular. Así mismo, aparece otra lesión de la misma característica en región umbilical. Se realizaron estudios histopatológicos y clínicos concluyéndose que se trata de la Cromomycosis (*Fonsecae Pedrosoi*). El tratamiento se realizó con Anfotericina B oral 300 mg/día que fue aumentándose cada dos semanas hasta llegar a un total de 2.400 mg/día

Las lesiones en piel a los dos meses curaron y se continúa el tratamiento hasta cumplir un año con excelente evolución. No hubo recurrencia al año siguiente.

Ficha presentada por el Dr. Ricardo Castillo P.